Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. operates healthcare-related subsidiaries that include a critical access acute care hospital, a behavioral health treatment business, a biotechnology subsidiary and Vector BioSource, a biospecimen and data sourcing provider for biotechnology, clinical research and pharmaceutical research customers.
Company news commonly covers clinical-capability additions at Big South Fork Medical Center, swing-bed and specialty-care arrangements, license and operating updates for Myrtle Recovery Centers, acquisition activity, capital-structure actions and trading-status developments for FOXO common stock on the OTC market.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its Board's approval to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which specializes in epigenetics technology. The subsidiary owns Patent No. 11,817,214 for machine learning models that determine biochemical states using DNA epigenetic data.
FOXO Labs utilizes saliva-based epigenetic biomarkers to provide health, lifestyle, and longevity insights, eliminating the need for invasive blood and urine collection. The company is developing an AI-powered health coaching system that combines wearable data with epigenetic analysis to deliver personalized wellness guidance.
The spin-off aims to create a subscription-based revenue model for personal health and longevity, with FOXO Technologies maintaining partial ownership while allowing shareholders to benefit from direct ownership in FOXO Labs.
FOXO Technologies (NYSE American: FOXO) has announced a 1-for-1.99 reverse stock split of its Class A common stock, effective July 27, 2025, at 4:01 PM ET. The stock will begin trading on a split-adjusted basis on July 28, 2025, under the same symbol but with a new CUSIP number.
The reverse split was approved on June 23, 2025, by a majority stockholder and aims to ensure compliance with NYSE American's continued listing requirement of maintaining a stock price above $0.10 per share. Fractional shares will be rounded up to the next whole number, and all outstanding securities, including preferred stock, debt, options, warrants, and equity incentive plans, will be proportionally adjusted.
FOXO Technologies Inc. (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has secured approval for Scott County Opioid Abatement Funds for a second consecutive year. The funding, effective July 1, 2025, will support care for uninsured patients from Scott County at the company's Oneida, Tennessee facility.
The facility is currently operating at full capacity with a patient waiting list, demonstrating strong demand for its services. Myrtle's CEO Robert Merritt highlighted this as validation of their clinical team's quality of care. FOXO's CEO Seamus Lagan indicated plans for expansion through organic growth and acquisitions, expecting Myrtle to become a significant revenue contributor to FOXO in the future.
FOXO Technologies (NYSE American: FOXO) has designated a new Series E Cumulative Redeemable Secured Preferred Stock to support its acquisition strategy. The Series E Preferred Stock features include a $25.00 per share stated value, 2.5% annual cash dividend (paid semi-annually), 5.0% annual common stock dividend (paid semi-annually), and security interest in FOXO Acquisition Corporation.
The company plans to use this preferred stock as both acquisition currency and for capital raising, with intentions to have it publicly listed with its own trading symbol. CEO Seamus Lagan emphasized this non-dilutive funding mechanism's potential to increase net revenues and cash flow through strategic acquisitions.
FOXO Technologies Inc. (NYSE American: FOXO) announced the expansion of services at its Big South Fork Medical Center in Oneida, Tennessee, to include wound care services starting June 2, 2025. The hospital, which currently serves over 600 emergency room patients and 300 outpatients monthly, will offer both inpatient and outpatient wound care services.
The expansion addresses a growing need for wound care services, particularly for diabetic patients. According to the CDC, as of 2021, over 38 million diabetes patients existed in the U.S., with up to 15% experiencing diabetic foot ulcers. The hospital is currently reconfiguring space and making key clinical hires to support this initiative.
FOXO Technologies (NYSE American: FOXO) announced significant operational achievements for its behavioral health subsidiary, Myrtle Recovery Centers. Since launching in Oneida, Tennessee in August 2023, the facility has:
- Treated over 400 patients
- Provided 5,000+ care days
- Projects 10,000 patient care days by end of 2025
Myrtle's CEO Robert Merritt highlighted the facility's strong reputation in East Tennessee for substance use disorder treatment. FOXO's CEO Seamus Lagan expressed satisfaction with the investment and indicated plans for expansion to additional locations to increase revenue contribution.
FOXO Technologies has completed a 1-for-10 reverse stock split effective April 28, 2025, at 4:01pm Eastern Time. The company's stock, trading under symbol FOXO on NYSE American, will begin post-split trading on April 29, 2025.
Key changes include:
- Common stock consolidation: Every 10 shares will combine into 1 share
- Share count reduction: From 38.7 million to approximately 3.87 million shares
- Par value remains unchanged at $0.0001
- Fractional shares will be rounded up to the next whole number
All outstanding preferred shares, stock options, warrants, and equity incentive plans will be adjusted accordingly. Continental Stock Transfer & Trust Company will serve as the exchange agent, providing instructions to stockholders of record for certificate exchange. Broker-held positions will adjust automatically.